Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS): Treatment effects and relation to coronary angiographic progression

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 5, 1996, Pages 697-704

  Mack, Wendy J ^a   Krauss, Ronald M ^c   Hodis, Howard N ^a,b,d  

^a Stat Consult and Research Center   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

angiographic trials; coronary angiography; coronary artery disease; lipoprotein subclasses; triglyceride rich lipoproteins

Indexed keywords

HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE SEVERITY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

EID: 0029986159     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.5.697     Document Type: Article

References (31)

1. Cashin-Hemphill L, Kramsch DM, Azen SP, DeMets D, DeBoer LWV, Hwang I, Vailas L, Hirsch LJ, Mack WJ, Hodis HN, Mahrer PR, Selzer RH, Alaupovic P, Blankenhorn DH. The Monitored Atherosclerosis Regression Study (MARS): design, methods, and baseline results. The Online Journal of Current Clinical Trials. 1992: Doc 26.
2. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
3. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/ moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
4. Alaupovic P. David Rubinstein Memorial Lecture: The biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can J Biochem. 1981;59: 565-579.
5. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol. 1995;6: 209-214.
6. Selzer RH, Hagerty C, Azen SP, Siebes M, Lee P, Shircore A, Blankenhorn DH. Precision and rcproducibility of quantitative coronary angiography with applications to controlled clinical trials: a sampling study. J Clin Invest. 1989;83:520-526.
7. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GJ, ed. Blood Lipids and Lipoproteins. New York, NY: John Wiley Interscience; 1972: 181-274.
8. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87: 1781-1791.
9. Azen SP, Mack WJ, Cashin-Hcmphill L, LaBree L, Shircore AM, Selzer RH, Blankenhorn DH, Hodis HN. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study (CLAS). Circulation. 1996;93:34-41.
10. Blankenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb. 1994;14:177-192.
11. Williams PT, Vranizan KM, Krauss RM. Correlations of plasma lipoproteins with LDL subfractions by particle size in men and women. J Lipid Res. 1992;33:765-774.
12. Mack WJ, Selzer RH, Pogoda JM, Lee PL, Shircore AM, Azen SP, Blankenhorn DH. Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. Arterioscler Thromb. 1992;12:348-356.
13. Kragel AH, Shanlhasundari GR, Wittes JT, Roberts WC. Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. Circulation. 1989;80: 1747-1756.
14. Kragel AH, Shanthasundari GR, Wittes JT, Roberts WC. Morphometric analysis of the composition of coronary arterial plaques in isolated unstable angina pectoris with pain at rest. Am J Cardiol. 1990;66:562-567.
15. Tatami R, Mabuchi R, Ueda K, Udea R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981;64:1174-1184.
16. Reardon MF, Nestel PJ, Craig KH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 1985;71:881-888.
17. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation. 1987;75:124-130.
18. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary disease in hypercholestcrolaemic men. Lancet. 1987;2:62-66.
19. Watts GF, Mandelia S, Brunt JNH, Slavin BM, Coitart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas' Atherosclerosis Regression Study (STARS). Metabolism. 1993;42:1461-1467.
20. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
21. Austin MA, King M-C, Vranizan KM, Krauss RM, Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
22. Le NA, Givson JC, Ginsberg HN. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res. 1988;29: 669-677.
23. Carlson LA, Ballantyne D. Changing relative proportions of apolipoproteins C-II and C-III of very low density lipoproteins in hypertriglyceridemia. Atherosclerosis. 1976;23:563-568.
24. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990;81:470-476.
25. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 1995;332:1491-1498.
26. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ, Fisher MR, Friedman L, Friedewald W, Detre KM, Epstein SE. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
27. Kempen HJ, Van Gent CM, Buytenhek R, Buis B. Association of cholesterol concentrations in low-density lipoprotein, high-density lipoprotein, and high-density lipoprotein subfractions, and of apolipoproteins AI and AII, with coronary stenosis and left ventricular function. J Lab Clin Med. 1987;109:19-26.
28. Drexel H, Amann FW, Beran J, Rentsch K, Candina R, Muntwyler J, Luethy A, Gasser T, Follath F. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation. 1994;90:2230-2235.
29. Sweetnam PM, Bolton CH, Yarnell JWG, Bainton D, Baker IA, Elwood PC, Miller NE. Associations of the HDL: and HDL, cholesterol subfractions with the development of ischemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 1994;90:769-774.
30. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
31. 3 cholesterol, apo A-I and apo A-II and increased risk of myocardial infarction. Circulation. 1992;85:22-29.